Stay updated with breaking news from Cure Research Program. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
New data show that Black women with node positive HR+/HER2- breast cancer have worse outcomes than their white counterparts, although the difference was no longer significant after adjustment for BMI.
Certain patients with hormone receptor-positive, HER2-negative breast cancer can safely forgo adjuvant chemotherapy, a study suggests.
Some postmenopausal women with breast cancer do not benefit from chemotherapy when it’s added to hormone therapy, according to initial results of a clinical trial. The findings apply to postmenopausal women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer that has spread to a limited number of lymph nodes, and whose recurrence risk is relatively low. The findings may save tens of thousands of postmenopausal women each year the time, money, and harmful side effects that come with chemotherapy infusions. This is the first evidence in ...